UnitedHealth Group reported third-quarter 2026 adjusted earnings of $4.69 per share, above the $4.14 LSEG analyst estimate cited by CNBC, and raised its full-year adjusted earnings outlook to at least $20.50 per share. The result strengthens the company's turnaround case, but management said medical costs remain elevated.
The quarter beat on earnings and revenue
Revenue was $112.69 billion, compared with the $111.40 billion estimate. Net income reached $4.11 billion, or $4.56 per share, up from $2.35 billion, or $2.59 per share, a year earlier.
Adjusted earnings exclude items including divestitures, restructuring and changes in reserves for unprofitable contracts. Investors should therefore track both adjusted and reported results rather than treating the two per-share figures as interchangeable.
The company lifted 2026 adjusted EPS guidance from a prior range of $19.50 to $20.00 to at least $20.50. The new floor is $0.50 above the top of the previous range, a 2.5% increase relative to that former upper bound.
Medical cost performance improved
UnitedHealth's medical care ratio was 88.4%, better than the 89.9% StreetAccount estimate. The ratio measures medical expenses relative to premiums, so a lower result generally supports insurance profitability.
The improvement does not mean cost pressure has disappeared. CFO Wayne DeVeydt said inpatient care and specialty pharmacy costs remained elevated. He also estimated that the independent dispute resolution process under the No Surprises Act added at least 100 basis points, or one percentage point, to total medical costs.
Management linked part of the improvement to value-based care, which pays providers for outcomes, quality and cost effectiveness rather than service volume. The company said acute hospital admissions among members fell 15% year over year through the quarter, while home-health admissions rose 10%. Those are company-reported operating indicators, not proof that every cost initiative will produce lasting savings.
AI is an efficiency tool, not the core earnings proof
UnitedHealth is deploying ambient-listening tools to reduce physician paperwork and expanding patient self-scheduling, which management said rose 27% year over year. The financial case still rests on claims costs, pricing, membership quality and execution across UnitedHealthcare and Optum.
What investors should watch
Key indicators are the fourth-quarter medical care ratio, specialty-drug trends, Medicare Advantage pricing, Optum Health margins and cash flow. Investors should also compare the new earnings floor with reported results after excluded items.
BTI's conclusion is that UnitedHealth delivered a credible beat-and-raise quarter, but the stock's recovery still depends on proving that medical-cost improvement persists beyond one period.